AbbVie ($ABBV) and InterMune ($ITMN) may have won at least a temporary reprieve in their fight to stop the EMA from releasing trial data on their drugs. But the powerful agency is vowing to battle it out in court as they insist that the pharma industry will benefit from a big dose of transparency. "If the court decides we have to stop the release of data, I think that would be the worst possible boomerang for the industry," EMA Executive Director Guido Rasi told Reuters in an interview. "The most powerful weapon we have to tackle distrust is transparency. Story